GFM
GLUE icon

GF Fund Management’s Monte Rosa Therapeutics GLUE Stock Holding History

GF Fund Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1K Buy
1,616
+163
+11% +$3.08K ﹤0.01% 419
2026
Q1 		$23.9K Buy
1,453
+174
+14% +$3.33K ﹤0.01% 482
2025
Q4 		$20.1K Sell
1,279
-38
-3% -$512 ﹤0.01% 510
2025
Q3 		$9.76K Sell
1,317
-255
-16% -$1.35K ﹤0.01% 558
2025
Q2 		$7.09K Hold
1,572
– – ﹤0.01% 601
2025
Q1 		$7.29K Buy
1,572
+282
+22% +$1.73K ﹤0.01% 599
2024
Q4 		$8.95K Buy
+1,290
New +$9.68K ﹤0.01% 563

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GF Fund Management's GLUE Position: Q2 2026 in Review

GF Fund Management increased its Monte Rosa Therapeutics (GLUE) stake by 11% in Q2 2026, buying an estimated $3.08K and bringing the position to 1,616 shares worth $39.1K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

GF Fund Management first reported a position in GLUE in Q4 2024 and has held it in 7 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • GF Fund Management held 1,616 shares of Monte Rosa Therapeutics worth $39.1K as of Q2 2026.
  • GF Fund Management bought 163 Monte Rosa Therapeutics shares in Q2 2026, an estimated $3.08K.
  • Monte Rosa Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #419 holding.
  • GF Fund Management first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.